From cell biology to therapy: ENMD-2076 in the treatment of multiple myeloma

Expert Opinion on Investigational Drugs

Volumn 20, Issue 7, 2011, Pages 1015-1028

  Zhang, Shuhong ^a   Farag, Sherif S ^a  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

apoptosis; aurora kinase inhibitor; multiple myeloma; tyrosine kinase inhibitor

Indexed keywords

1 CYCLOPROPYL 3 [3 (5 MORPHOLINOMETHYL 1H BENZIMIDAZOL 2 YL) 1H PYRAZOL 4 YL]UREA; 2 (2 PHENYLVINYL) 4 [4 METHYLPIPERAZIN 1 YL] 6 (5 METHYL 2H PYRAZOL 3 YL AMINO)PYRIMIDINE; ALISERTIB; ANTINEOPLASTIC AGENT; AURORA A KINASE; AURORA B KINASE; AURORA C KINASE; AURORA KINASE INHIBITOR; BARASERTIB; BORTEZOMIB; CELL CYCLE PROTEIN; CYTOKINE; DEXAMETHASONE; DOXORUBICIN; ENMD 2076; ENMD 981693; FIBROBLAST GROWTH FACTOR; FIBROBLAST GROWTH FACTOR RECEPTOR; LENALIDOMIDE; PAZOPANIB; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; SEMAXANIB; TOZASERTIB; TYROSINE KINASE RECEPTOR; UNCLASSIFIED DRUG; VANDETANIB; VE 465;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ANOREXIA; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; BONE MARROW SUPPRESSION; BREAST CANCER; CANCER RELAPSE; CELL CYCLE ARREST; CELL PROLIFERATION; CELL SURVIVAL; CHRONIC LYMPHATIC LEUKEMIA; CHRONIC MYELOID LEUKEMIA; COLORECTAL TUMOR; CONGESTIVE HEART FAILURE; CYTOKINE RELEASE; CYTOTOXICITY; DIARRHEA; DOSE RESPONSE; DRUG ABSORPTION; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MEGADOSE; DRUG POTENTIATION; DRUG TARGETING; DYSPNEA; ELECTROLYTE DISTURBANCE; ENZYME INHIBITION; FATIGUE; HUMAN; HYPERTENSION; IC 50; IN VITRO STUDY; IN VIVO STUDY; LEUKOPENIA; MAXIMUM TOLERATED DOSE; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; MYELODYSPLASTIC SYNDROME; MYELOID METAPLASIA; MYELOMA CELL; NAUSEA; NEUTROPENIA; NONHUMAN; OVARY CANCER; OVARY TUMOR; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); POSTERIOR REVERSIBLE ENCEPHALOPATHY SYNDROME; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEINURIA; SIDE EFFECT; SIGNAL TRANSDUCTION; SOLID TUMOR; THROMBOCYTOPENIA; TREATMENT RESPONSE; TUMOR VOLUME;

ANIMALS; ANTINEOPLASTIC AGENTS; CLINICAL TRIALS AS TOPIC; HUMANS; MULTIPLE MYELOMA; PYRAZOLES; PYRIMIDINES; SIGNAL TRANSDUCTION; TREATMENT OUTCOME;

EID: 79958817256     PISSN: 13543784     EISSN: 17447658     Source Type: Journal    
DOI: 10.1517/13543784.2011.584869     Document Type: Article

References (104)

1. Barlogie B, Shaughnessy J, Tricot G, et al. Treatment of multiple myeloma. Blood 2004;103(1):20-32 (Pubitemid 38029914)
2. Tsuchiya J, Murakami H, Kanoh T, et al. Ten-year survival and prognostic factors in multiple myeloma. Japan Myeloma Study Group. Br J Haematol 1994;87(4):832-4 (Pubitemid 24264658)
3. Alexanian R, Barlogie B, Tucker S. VAD-based regimens as primary treatment for multiple myeloma. Am J Hematol 1990;33(2):86-9 (Pubitemid 20040083)
4. Riccardi A, Mora O, Tinelli C, et al. Long-term survival of stage I multiple myeloma given chemotherapy just after diagnosis or at progression of the disease: a multicentre randomized study. Cooperative Group of Study and Treatment of Multiple Myeloma. Br J Cancer 2000;82(7):1254-60 (Pubitemid 30145341)
5. Attal M, Harousseau JL, Stoppa AM, et al. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Francais du Myelome. N Engl J Med 1996;335(2):91-7 (Pubitemid 26240110)
6. Child JA, Morgan GJ, Davies FE, et al. High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N Engl J Med 2003;348(19):1875-83 (Pubitemid 36532313)
7. Attal M, Harousseau JL, Facon T, et al. Single versus double autologous stem-cell transplantation for multiple myeloma. N Engl J Med 2003;349(26):2495-502 (Pubitemid 38010075)
8. Dimopoulos M, Spencer A, Attal M, et al. Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma. N Engl J Med 2007;357(21):2123-32 (Pubitemid 350146107)
9. Podar K, Richardson PG, Hideshima T, et al. The malignant clone and the bone-marrow environment. Best Pract Res Clin Haematol 2007;20(4):597-612 (Pubitemid 350215375)
10. Rajkumar SV, Blood E, Vesole D, et al. Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: a clinical trial coordinated by the Eastern Cooperative Oncology Group. J Clin Oncol 2006;24(3):431-6 (Pubitemid 46630462)
11. Rajkumar SV, Rosinol L, Hussein M, et al. Multicenter, randomized, double-blind, placebo-controlled study of thalidomide plus dexamethasone compared with dexamethasone as initial therapy for newly diagnosed multiple myeloma. J Clin Oncol 2008;26(13):2171-7
12. Orlowski RZ, Nagler A, Sonneveld P, et al. Randomized Phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: combination therapy improves time to progression. J Clin Oncol 2007;25(25):3892-901 (Pubitemid 47477266)
13. Palumbo A, Bringhen S, Liberati AM, et al. Oral melphalan, prednisone, and thalidomide in elderly patients with multiple myeloma: updated results of a randomized controlled trial. Blood 2008;112(8):3107-14
14. van de Donk NW, Lokhorst HM, Dimopoulos M, et al. Treatment of relapsed and refractory multiple myeloma in the era of novel agents. Cancer Treat Rev 2010;37(4):266-83
15. Dingli D, Rajkumar SV. How best to use new therapies in multiple myeloma. Blood Rev 2010;24(3):91-100
16. Mahindra A, Hideshima T, Anderson KC. Multiple myeloma: biology of the disease. Blood Rev 2010;24(Suppl 1):S5-11
17. Hideshima T, Bergsagel PL, Kuehl WM, Anderson KC. Advances in biology of multiple myeloma: clinical applications. Blood 2004;104(3):607-18 (Pubitemid 38970551)
18. Mitsiades CS, Hideshima T, Chauhan D, et al. Emerging treatments for multiple myeloma: beyond immunomodulatory drugs and bortezomib. Semin Hematol 2009;46(2):166-75
19. Tiedemann RE, Zhu YX, Schmidt J, et al. Kinome-wide RNAi studies in human multiple myeloma identify vulnerable kinase targets, including a lymphoid-restricted kinase, GRK6. Blood 2010;115(8):1594-604
20. Wang X, Sinn AL, Pollok K, et al. Preclinical activity of a novel multiple tyrosine kinase and aurora kinase inhibitor, ENMD-2076, against multiple myeloma. Br J Haematol 2010;150(3):313-25
21. Fletcher GC, Brokx RD, Denny TA, et al. ENMD-2076 Is an orally-active kinase inhibitor with antiangiogenic and antiproliferative mechanisms of action. Mol Cancer Ther 2011;10(1):126-37
22. Diamond JR, Bastos BR, Hansen RJ, et al. Phase I safety, pharmacokinetic and pharmacodynamic study of enmd-2076, a novel angiogenic and aurora kinase inhibitor, in patients with advanced solid tumors. Clin Cancer Res 2011;17(4):849-60
23. Tentler JJ, Bradshaw-Pierce EL, Serkova NJ, et al. Assessment of the in vivo antitumor effects of ENMD-2076, a novel multitargeted kinase inhibitor, against primary and cell line-derived human colorectal cancer xenograft models. Clin Cancer Res 2010;16(11):2989-98
24. Kumar S, Gertz MA, Dispenzieri A, et al. Response rate, durability of response, and survival after thalidomide therapy for relapsed multiple myeloma. Mayo Clin Proc 2003;78(1):34-9 (Pubitemid 36033958)
25. Chauhan D, Uchiyama H, Akbarali Y, et al. Multiple myeloma cell adhesion-induced interleukin-6 expression in bone marrow stromal cells involves activation of NF-kappa B. Blood 1996;87(3):1104-12 (Pubitemid 26043538)
26. Damiano JS, Cress AE, Hazelhurst LA, et al. Cell adhesion mediated drug-resistance (CAM-DR): role of integrins and resistance to apoptosis in human cell lines. Blood 1999;93:1658-67 (Pubitemid 29102494)
27. Gupta D, Treon SP, Shima Y, et al. Adherence of multiple myeloma cells to bone marrow stromal cells upregulates vascular endothelial growth factor secretion: therapeutic applications. Leukemia 2001;15(12):1950-61 (Pubitemid 33115003)
28. Hideshima T, Podar K, Chauhan D, Anderson KC. Cytokines and signal transduction. Best Pract Res Clin Haematol 2005;18(4):509-24 (Pubitemid 40984111)
29. Bataille R, Jourdan M, Zhang XG, Klein B. Serum levels of interleukin 6, a potent myeloma cell growth factor, as a reflect of disease severity in plasma cell dyscrasias. J Clin Invest 1989;84(6):2008-11 (Pubitemid 20016211)
30. Ludwig H, Nachbaur DM, Fritz E, et al. Interleukin-6 is a prognostic factor in multiple myeloma. Blood 1991;77(12):2794-5
31. Hallek M, Bergsagel PL, Anderson KC. Multiple myeloma: increasing evidence for a multistep transformation process. Blood 1998;91(1):3-21 (Pubitemid 28018724)
32. Jelinek DF. Mechanisms of myeloma cell growth control. Hematol Oncol Clin North Am 1999;13(6):1145-57 (Pubitemid 30017391)
33. Heinrich PC, Behrmann I, Muller-Newen G, et al. Interleukin-6-type cytokine signalling through the gp130/Jak/STAT pathway. Biochem J 1998;334(Pt 2):297-314 (Pubitemid 28448572)
34. Ogata A, Chauhan D, Teoh G, et al. IL-6 triggers cell growth via the Ras-dependent mitogen-activated protein kinase cascade. J Immunol 1997;159(5):2212-21 (Pubitemid 127681011)
35. Billadeau D, Jelinek DF, Shah N, et al. Introduction of an activated N-ras oncogene alters the growth characteristics of the interleukin 6-dependent myeloma cell line ANBL6. Cancer Res 1995;55(16):3640-6
36. Catlett-Falcone R, Landowski TH, Oshiro MM, et al. Constitutive activation of Stat3 signaling confers resistance to apoptosis in human U266 myeloma cells. Immunity 1999;10(1):105-15 (Pubitemid 29077388)
37. Puthier D, Bataille R, Amiot M. IL-6 up-regulates mcl-1 in human myeloma cells through JAK/STAT rather than ras/MAP kinase pathway. Eur J Immunol 1999;29(12):3945-50
38. Choi Y, Zhang J, Murga C, et al. PTEN, but not SHIP and SHIP2, suppresses the PI3K/Akt pathway and induces growth inhibition and apoptosis of myeloma cells. Oncogene 2002;21(34):5289-300 (Pubitemid 34948140)
39. Derenne S, Monia B, Dean NM, et al. Antisense strategy shows that Mcl-1 rather than Bcl-2 or Bcl-x(L) is an essential survival protein of human myeloma cells. Blood 2002;100(1):194-9 (Pubitemid 35177447)
40. Vivanco I, Sawyers CL. The phosphatidylinositol 3-Kinase AKT pathway in human cancer. Nat Rev Cancer 2002;2(7):489-501 (Pubitemid 37328931)
41. Brunet A, Bonni A, Zigmond MJ, et al. Akt promotes cell survival by phosphorylating and inhibiting a Forkhead transcription factor. Cell 1999;96(6):857-68 (Pubitemid 29165088)
42. Vanderkerken K, Asosingh K, Braet F, et al. Insulin-like growth factor-1 acts as a chemoattractant factor for 5T2 multiple myeloma cells. Blood 1999;93(1):235-41 (Pubitemid 29019408)
43. Agrawal NR, Bukowski RM, Rybicki LA, et al. A Phase I-II trial of polyethylene glycol-conjugated L-asparaginase in patients with multiple myeloma. Cancer 2003;98(1):94-9 (Pubitemid 36741131)
44. Hideshima T, Chauhan D, Richardson P, et al. NF-kappa B as a therapeutic target in multiple myeloma. J Biol Chem 2002;277(19):16639-47 (Pubitemid 34967682)
45. Mitsiades CS, Mitsiades NS, McMullan CJ, et al. Inhibition of the insulin-like growth factor receptor-1 tyrosine kinase activity as a therapeutic strategy for multiple myeloma, other hematologic malignancies, and solid tumors. Cancer Cell 2004;5(3):221-30 (Pubitemid 38402114)
46. Ogawa M, Nishiura T, Oritani K, et al. Cytokines prevent dexamethasone-induced apoptosis via the activation of mitogen-activated protein kinase and phosphatidylinositol 3-kinase pathways in a new multiple myeloma cell line. Cancer Res 2000;60(15):4262-9 (Pubitemid 30636615)
47. Qiang YW, Kopantzev E, Rudikoff S. Insulinlike growth factor-I signaling in multiple myeloma: downstream elements, functional correlates, and pathway cross-talk. Blood 2002;99(11):4138-46 (Pubitemid 35332058)
48. Schimmer AD. Inhibitor of apoptosis proteins: translating basic knowledge into clinical practice. Cancer Res 2004;64(20):7183-90 (Pubitemid 39372048)
49. Podar K, Catley LP, Tai YT, et al. GW654652, the pan-inhibitor of VEGF receptors, blocks the growth and migration of multiple myeloma cells in the bone marrow microenvironment. Blood 2004;103(9):3474-9 (Pubitemid 38525680)
50. Dias S, Shmelkov SV, Lam G, Rafii S. VEGF(165) promotes survival of leukemic cells by Hsp90-mediated induction of Bcl-2 expression and apoptosis inhibition. Blood 2002;99(7):2532-40 (Pubitemid 34525442)
51. Le Gouill S, Podar K, Amiot M, et al. VEGF induces Mcl-1 up-regulation and protects multiple myeloma cells against apoptosis. Blood 2004;104(9):2886-92 (Pubitemid 39434976)
52. Bisping G, Leo R, Wenning D, et al. Paracrine interactions of basic fibroblast growth factor and interleukin-6 in multiple myeloma. Blood 2003;101(7):2775-83 (Pubitemid 36857643)
53. Chesi M, Brents LA, Ely SA, et al. Activated fibroblast growth factor receptor 3 is an oncogene that contributes to tumor progression in multiple myeloma. Blood 2001;97(3):729-36 (Pubitemid 32113407)
54. Otsuki T, Yamada O, Yata K, et al. Expression of fibroblast growth factor and FGF-receptor family genes in human myeloma cells, including lines possessing t(4;14)(q16.3;q32. 3) and FGFR3 translocation. Int J Oncol 1999;15(6):1205-12
55. Chesi M, Nardini E, Brents LA, et al. Frequent translocation t(4;14)(p16.3; q32.3) in multiple myeloma is associated with increased expression and activating mutations of fibroblast growth factor receptor 3. Nat Genet 1997;16(3):260-4 (Pubitemid 27280209)
56. Moreau P, Attal M, Garban F, et al. Heterogeneity of t(4;14) in multiple myeloma. Long-term follow-up of 100 cases treated with tandem transplantation in IFM99 trials. Leukemia 2007;21(9):2020-4 (Pubitemid 47299977)
57. Chng WJ, Braggio E, Mulligan G, et al. The centrosome index is a powerful prognostic marker in myeloma and identifies a cohort of patients that might benefit from aurora kinase inhibition. Blood 2008;111(3):1603-9 (Pubitemid 351213451)
58. Kanai M, Goke M, Tsunekawa S, Podolsky DK. Signal transduction pathway of human fibroblast growth factor receptor 3. Identification of a novel 66-kDa phosphoprotein. J Biol Chem 1997;272(10):6621-8 (Pubitemid 27118147)
59. Hart KC, Robertson SC, Kanemitsu MY, et al. Transformation and Stat activation by derivatives of FGFR1, FGFR3, and FGFR4. Oncogene 2000;19(29):3309-20 (Pubitemid 30487417)
60. Plowright EE, Li Z, Bergsagel PL, et al. Ectopic expression of fibroblast growth factor receptor 3 promotes myeloma cell proliferation and prevents apoptosis. Blood 2000;95(3):992-8 (Pubitemid 30062723)
61. Paterson JL, Li Z, Wen XY, et al. Preclinical studies of fibroblast growth factor receptor 3 as a therapeutic target in multiple myeloma. Br J Haematol 2004;124(5):595-603 (Pubitemid 38297091)
62. Andrews PD, Knatko E, Moore WJ, Swedlow JR. Mitotic mechanics: the auroras come into view. Curr Opin Cell Biol 2003;15(6):672-83 (Pubitemid 37487960)
63. Katayama H, Brinkley WR, Sen S. The Aurora kinases: role in cell transformation and tumorigenesis. Cancer Metastasis Rev 2003;22(4):451-64 (Pubitemid 36791899)
64. Gautschi O, Heighway J, Mack PC, et al. Aurora kinases as anticancer drug targets. Clin Cancer Res 2008;14(6):1639-48 (Pubitemid 351471713)
65. Hirota T, Kunitoku N, Sasayama T, et al. Aurora-A and an interacting activator, the LIM protein Ajuba, are required for mitotic commitment in human cells. Cell 2003;114(5):585-98 (Pubitemid 37159255)
66. Cazales M, Schmitt E, Montembault E, et al. CDC25B phosphorylation by Aurora-A occurs at the G2/M transition and is inhibited by DNA damage. Cell Cycle 2005;4(9):1233-8 (Pubitemid 41365395)
67. Lens SM, Rodriguez JA, Vader G, et al. Uncoupling the central spindle-associated function of the chromosomal passenger complex from its role at centromeres. Mol Biol Cell 2006;17(4):1897-909 (Pubitemid 44011605)
68. Mountzios G, Terpos E, Dimopoulos MA. Aurora kinases as targets for cancer therapy. Cancer Treat Rev 2008;34(2):175-82 (Pubitemid 351372885)
69. Manfredi MG, Ecsedy JA, Meetze KA, et al. Antitumor activity of MLN8054, an orally active small-molecule inhibitor of aurora a kinase. Proc Natl Acad Sci USA 2007;104(10):4106-11 (Pubitemid 47181586)
70. Fonseca R, Barlogie B, Bataille R, et al. Genetics and cytogenetics of multiple myeloma: a workshop report. Cancer Res 2004;64(4):1546-58 (Pubitemid 38235629)
71. Hose D, Reme T, Meissner T, et al. Inhibition of aurora kinases for tailored risk-adapted treatment of multiple myeloma. Blood 2009;113(18):4331-40
72. Bray MR, Fletcher GC, Denny TA, et al. ENMD-981693 is an orally-active kinase inhibitor with activity towards human hematologic cancers in vitro and in vivo. Blood 2006;108:Abstract 1377
73. Adams JM, Cory S. The Bcl-2 protein family: arbiters of cell survival. Science 1998;281(5381):1322-6 (Pubitemid 28406819)
74. Puthier D, Pellat-Deceunynck C, Barille S, et al. Differential expression of Bcl-2 in human plasma cell disorders according to proliferation status and malignancy. Leukemia 1999;13(2):289-94 (Pubitemid 29092663)
75. Miguel-Garcia A, Orero T, Matutes E, et al. Bcl-2 expression in plasma cells from neoplastic gammopathies and reactive plasmacytosis: a comparative study. Haematologica 1998;83(4):298-304 (Pubitemid 28217849)
76. Vairo G, Innes KM, Adams JM. Bcl-2 has a cell cycle inhibitory function separable from its enhancement of cell survival. Oncogene 1996;13(7):1511-19 (Pubitemid 26354199)
77. Huang DC, O'Reilly LA, Strasser A, Cory S. The anti-apoptosis function of Bcl-2 can be genetically separated from its inhibitory effect on cell cycle entry. Embo J 1997;16(15):4628-38 (Pubitemid 27326600)
78. Tu Y, Renner S, Xu F, et al. BCL-X expression in multiple myeloma: possible indicator of chemoresistance. Cancer Res 1998;58(2):256-62 (Pubitemid 28047064)
79. Gojo I, Zhang B, Fenton RG. The cyclin-dependent kinase inhibitor flavopiridol induces apoptosis in multiple myeloma cells through transcriptional repression and down-regulation of Mcl-1. Clin Cancer Res 2002;8(11):3527-38 (Pubitemid 35340731)
80. Gomez-Bougie P, Bataille R, Amiot M. The imbalance between Bim and Mcl-1 expression controls the survival of human myeloma cells. Eur J Immunol 2004;34(11):3156-64 (Pubitemid 39549394)
81. Mitsiades CS, Mitsiades N, Poulaki V, et al. Activation of NF-kappaB and upregulation of intracellular anti-apoptotic proteins via the IGF-1/Akt signaling in human multiple myeloma cells: therapeutic implications. Oncogene 2002;21(37):5673-83 (Pubitemid 35333000)
82. Nakagawa Y, Abe S, Kurata M, et al. IAP family protein expression correlates with poor outcome of multiple myeloma patients in association with chemotherapy-induced overexpression of multidrug resistance genes. Am J Hematol 2006;81(11):824-31 (Pubitemid 44682183)
83. Romagnoli M, Trichet V, David C, et al. Significant impact of survivin on myeloma cell growth. Leukemia 2007;21(5):1070-8 (Pubitemid 46672084)
84. Younes H, Leleu X, Hatjiharissi E, et al. Targeting the phosphatidylinositol 3-kinase pathway in multiple myeloma. Clin Cancer Res 2007;13(13):3771-5 (Pubitemid 47037580)
85. Schultz WA. Molcular Biology of Human Cancers. Norwell, MA: Springer, 2005
86. Letai A. Growth factor withdrawal and apoptosis: the middle game. Mol Cell 2006;21(6):728-30 (Pubitemid 43376121)
87. Yokogami K, Wakisaka S, Avruch J, Reeves SA. Serine phosphorylation and maximal activation of STAT3 during CNTF signaling is mediated by the rapamycin target mTOR. Curr Biol 2000;10(1):47-50 (Pubitemid 30057415)
88. Hauf S, Cole RW, LaTerra S, et al. The small molecule Hesperadin reveals a role for Aurora B in correcting kinetochore-microtubule attachment and in maintaining the spindle assembly checkpoint. J Cell Biol 2003;161(2):281-94 (Pubitemid 36529847)
89. Honda R, Korner R, Nigg EA. Exploring the functional interactions between Aurora B, INCENP, and survivin in mitosis. Mol Biol Cell 2003;14(8):3325-41 (Pubitemid 37013130)
90. Meraldi P, Honda R, Nigg EA. Aurora kinases link chromosome segregation and cell division to cancer susceptibility. Curr Opin Genet Dev 2004;14(1):29-36 (Pubitemid 38167474)
91. Hembrough TA, Chen X, Burke PA, et al. Inhibition of multiple myeloma tumor growth and FGFR3 by the aurora-angiogenesis inhibitor ENMD-981693. Blood (ASH Annual Meeting Abstracts) 2007;110:Abstract 1209
92. Farag SS, Zhang S, Suvannasankha A, et al. Clinical activity of a novel multiple tyrosine kinase and aurora kinase inhibitor, ENMD-2076, against multiple myeloma: Interim Phase I Trial Results 52nd ASH Annual Metting and Exposition; 2010; Orlando, FL; 2010. p. Abstract 1957
93. Yee KW, Brandwein J, MInden MD, et al. A Phase I study of ENMD-2076 in patients with relapsed or refractory acute myeloid leukemia (AML). Mol Cancer Ther 2009;8(12 Suppl):A106
94. Evans R, Naber C, Steffler T, et al. Aurora a kinase RNAi and small molecule inhibition of aurora kinases with VE-465 induce apoptotic death in multiple myeloma cells. Leuk Lymphoma 2008;49(3):559-69 (Pubitemid 351298342)
95. Evans RP, Naber C, Steffler T, et al. The selective Aurora B kinase inhibitor AZD1152 is a potential new treatment for multiple myeloma. Br J Haematol 2008;140(3):295-302
96. Santo L, Hideshima T, Cirstea D, et al. Anti-myeloma activity of a multi targeted kinase inhibitor, AT9283, via potent Aurora Kinase and STAT3 inhibition either alone or in combination with lenalidomide. Clin Cancer Res 2011. [Epub ahead of print]
97. Negri JM, McMillin DW, Delmore J, et al. In vitro anti-myeloma activity of the Aurora kinase inhibitor VE-465. Br J Haematol 2009;147(5):672-6
98. Gorgun G, Calabrese E, Hideshima T, et al. A novel Aurora-A kinase inhibitor MLN8237 induces cytotoxicity and cell-cycle arrest in multiple myeloma. Blood 2010;115(25):5202-13
99. Kovacs MJ, Reece DE, Marcellus D, et al. A Phase II study of ZD6474 (Zactima, a selective inhibitor of VEGFR and EGFR tyrosine kinase in patients with relapsed multiple myeloma-NCIC CTG IND.145. Invest New Drugs 2006;24(6):529-35 (Pubitemid 44273029)
100. Prince HM, Honemann D, Spencer A, et al. Vascular endothelial growth factor inhibition is not an effective therapeutic strategy for relapsed or refractory multiple myeloma: a Phase II study of pazopanib (GW786034). Blood 2009;113(19):4819-20
101. Zangari M, Anaissie E, Stopeck A, et al. Phase II study of SU5416, a small molecule vascular endothelial growth factor tyrosine kinase receptor inhibitor, in patients with refractory multiple myeloma. Clin Cancer Res 2004;10(1 Pt 1):88-95 (Pubitemid 38114166)
102. Farag SS, Zhang S, Jansak BS, et al. Phase II trial of temsirolimus in patients with relapsed or refractory multiple myeloma. Leuk Lymphoma 2009;33:1475-80
103. Wang X, Sinn AL, Suvannasankha A, et al. The Novel Aurora Kinase Inhibitor ENMD-2076 Has Potent Single Agent Activity against Multiple Myeloma (MM) in vitro and in vivo, and Shows Synergistic Activity in Combination with Lenalidomide. Blood (ASH Annual Meeting Abstracts) 2008;112:Abstract 3660
104. Bissery MC, Guenard D, Gueritte-Voegelein F, Lavelle F. Experimental antitumor activity of taxotere (RP 56976, NSC 628503), a taxol analogue. Cancer Res 1991;51(18):4845-52